Pardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
07. November 2022 16:01 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug...
Pardes Biosciences to Present at Jefferies London Healthcare Conference
01. November 2022 08:30 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel...
Pardes Biosciences Appoints Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to Board of Directors
14. September 2022 08:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel oral...
Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 Infections
13. September 2022 08:00 ET
|
Pardes Biosciences, Inc
Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral activity, safety, and efficacy of PBI-0451 versus placebo Interim data from Phase 2 anticipated in Q1...
Pardes Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
12. September 2022 08:30 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel...
Pardes Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
15. August 2022 08:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug...
Pardes Biosciences to Present at Jefferies Global Healthcare Conference
01. Juni 2022 08:30 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel...
Pardes Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
10. Mai 2022 16:01 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel...
Pardes Biosciences Reports Full Year 2021 Financial Results and Provides Business Update
29. März 2022 16:05 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel...
Pardes Biosciences to Present at the International Conference On Antiviral Research 2022
21. März 2022 07:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif. , March 21, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel...